Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor 360mg vs Prasugrel 60mg in STEMI (RAPID 2)
NCT01805570Phase 4
Key facts
- Status
- Completed
- Start
- Nov 2012
- Primary completion
- Mar 2013
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- ticagrelorprasugrel
- Conditions
- ST-elevation myocardial infarction (STEMI)
01
Overview
Phase 4, randomised, open-label trial of ticagrelor and prasugrel in ST-elevation myocardial infarction (STEMI). Started Nov 2012; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with STEMI within 12 hours of symptom onset, aged 18-75, undergoing primary PCI with bivalirudin.
04
Registry description
The aim of the RAPID study is to evaluate the superiority rapid onset of action of Ticagrelor 360 mg LD versus Prasugrel 60 mg LD, in 50 patients with STEMI (ST segment elevation myocardial infarction) undergoing PPCI with bivalirudin monotherapy. Secondary study aim is to found out clinical predictors of high residual platelet reactivity in the first hour after a novel oral antiplatelet agent LD.
Beyond the preview
Go deeper on NCT01805570.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805570.